440 related articles for article (PubMed ID: 35182296)
21. Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy.
Crombie JL; Graff T; Falchi L; Karimi YH; Bannerji R; Nastoupil L; Thieblemont C; Ursu R; Bartlett N; Nachar V; Weiss J; Osterson J; Patel K; Brody J; Abramson JS; Lunning M; Shah NN; Ayed A; Kamdar M; Parsons B; Caimi P; Flinn I; Herrera A; Sharman J; McKenna M; Armand P; Kahl B; Smith S; Zelenetz A; Budde LE; Hutchings M; Phillips T; Dickinson M
Blood; 2024 Apr; 143(16):1565-1575. PubMed ID: 38252906
[TBL] [Abstract][Full Text] [Related]
22. Challenges and solutions to superior chimeric antigen receptor-T design and deployment for B-cell lymphomas.
Gao J; Dahiya S; Patel SA
Br J Haematol; 2023 Oct; 203(2):161-168. PubMed ID: 37488074
[TBL] [Abstract][Full Text] [Related]
23. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.
Tapia-Galisteo A; Álvarez-Vallina L; Sanz L
J Hematol Oncol; 2023 Jul; 16(1):83. PubMed ID: 37501154
[TBL] [Abstract][Full Text] [Related]
24. Emerging new cell therapies/immune therapies in B-cell non-Hodgkin's lymphoma.
Banerjee T; Vallurupalli A
Curr Probl Cancer; 2022 Feb; 46(1):100825. PubMed ID: 35033383
[TBL] [Abstract][Full Text] [Related]
25. Redirecting T cells to hematological malignancies with bispecific antibodies.
Velasquez MP; Bonifant CL; Gottschalk S
Blood; 2018 Jan; 131(1):30-38. PubMed ID: 29118005
[TBL] [Abstract][Full Text] [Related]
26. Factors Affecting the Cancer Immunotherapeutic Efficacy of T Cell Bispecific Antibodies and Strategies for Improvement.
Long M; Mims AS; Li Z
Immunol Invest; 2022 Nov; 51(8):2176-2214. PubMed ID: 36259611
[TBL] [Abstract][Full Text] [Related]
27. Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma.
Heini AD; Bacher U; Porret N; Wiedemann G; Legros M; Stalder Zeerleder D; Seipel K; Novak U; Daskalakis M; Pabst T
Cells; 2022 Sep; 11(17):. PubMed ID: 36078155
[TBL] [Abstract][Full Text] [Related]
28. Donor-derived and off-the-shelf allogeneic anti-CD19 CAR T-cell therapy for R/R ALL and NHL: A systematic review and meta-analysis.
Chen S; Zhang Y; Fang C; Zhang N; Wang Y; Chen R; Li Y; Tu S
Crit Rev Oncol Hematol; 2022 Nov; 179():103807. PubMed ID: 36087853
[TBL] [Abstract][Full Text] [Related]
29. Taking a BiTE out of Lymphoma: Bispecific Antibodies in B-Cell Non-Hodgkin Lymphoma.
Weiss JM; Phillips TJ
Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730677
[TBL] [Abstract][Full Text] [Related]
30. Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma.
Zinzani PL; Minotti G
J Cancer Res Clin Oncol; 2022 Jan; 148(1):177-190. PubMed ID: 34741682
[TBL] [Abstract][Full Text] [Related]
31. Thinking "outside the germinal center": Re-educating T cells to combat follicular lymphoma.
Kambhampati S; Shouse G; Danilov AV
Blood Rev; 2023 Sep; 61():101099. PubMed ID: 37173225
[TBL] [Abstract][Full Text] [Related]
32. Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial.
Matasar M; Bartlett NL; Shadman M; Budde LE; Flinn I; Gregory GP; Kim WS; Hess G; El-Sharkawi D; Diefenbach CS; Huang H; To I; Parreira J; Wu M; Kwan A; Assouline S
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):240-253. PubMed ID: 38195322
[TBL] [Abstract][Full Text] [Related]
33. Dual target dilemma: navigating epcoritamab vs. glofitamab in relapsed refractory diffuse large B-cell lymphoma.
Davis JA; Granger K; Sakowski A; Goodwin S; Herbst A; Smith D; Hendrickson L; Nachar VR
Expert Rev Hematol; 2023; 16(12):915-918. PubMed ID: 37982732
[No Abstract] [Full Text] [Related]
34. Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives.
Abou Dalle I; Dulery R; Moukalled N; Ricard L; Stocker N; El-Cheikh J; Mohty M; Bazarbachi A
Blood Cancer J; 2024 Jan; 14(1):23. PubMed ID: 38272863
[TBL] [Abstract][Full Text] [Related]
35. Bispecific Antibodies in the Treatment of Multiple Myeloma.
Zhou X; Xiao X; Kortuem KM; Einsele H
Hematol Oncol Clin North Am; 2024 Apr; 38(2):361-381. PubMed ID: 38199897
[TBL] [Abstract][Full Text] [Related]
36. The value of bispecific antibodies in relapsed and refractory DLBCL.
Lewis KL; Cheah CY
Leuk Lymphoma; 2024 Jun; 65(6):720-735. PubMed ID: 38454535
[TBL] [Abstract][Full Text] [Related]
37. T-cell-engaging bispecific antibodies in cancer.
van de Donk NWCJ; Zweegman S
Lancet; 2023 Jul; 402(10396):142-158. PubMed ID: 37271153
[TBL] [Abstract][Full Text] [Related]
38. Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma.
Tacchetti P; Talarico M; Barbato S; Pantani L; Mancuso K; Rizzello I; Zamagni E; Cavo M
Expert Rev Anticancer Ther; 2024 Jun; 24(6):379-395. PubMed ID: 38798125
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy in indolent Non-Hodgkin's Lymphoma.
Amhaz G; Bazarbachi A; El-Cheikh J
Leuk Res Rep; 2022; 17():100325. PubMed ID: 35663281
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
